Jane B. Neckers

Jane Trepel came to the NCI from the Laboratory of Preclinical Pharmacology, National Institute of Mental Health, where she identified posttranslational modification of glycoprotein hormones by ADP-ribosylation. Since then she has held positions of increasing responsibility in the former Clinical Pharmacology Branch and Medicine Branch. She is the author of five issued and pending patents in new drug development and is the recipient of a Federal Technology Transfer Award. Her interests are focused on the new therapeutic opportunities provided by molecular dissection of aberrant tumor cell signaling pathways.
1) drug development
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson CC, Room 12N230
Bethesda, MD 20892
Ph: 240-760-6330
trepelj@mail.nih.gov
Selected Publications
- Future Med Chem. 5: 1059-71, 2013. [ Journal Article ]
- Proc. Natl. Acad. Sci. U.S.A.. 110: E1604-12, 2013. [ Journal Article ]
- Oncotarget. 4: 1065-74, 2013. [ Journal Article ]
- Haematologica. 99: e81-3, 2014. [ Journal Article ]
- Mol. Cell. 53: 317-29, 2014. [ Journal Article ]
Jane Trepel came to the NCI from the Laboratory of Preclinical Pharmacology, National Institute of Mental Health, where she identified posttranslational modification of glycoprotein hormones by ADP-ribosylation. Since then she has held positions of increasing responsibility in the former Clinical Pharmacology Branch and Medicine Branch. She is the author of five issued and pending patents in new drug development and is the recipient of a Federal Technology Transfer Award. Her interests are focused on the new therapeutic opportunities provided by molecular dissection of aberrant tumor cell signaling pathways.
Name | Position |
---|---|
Jonathan Baker | Postbaccalaureate Fellow (CRTA) |
Leah N. Franklin | Postbaccalaureate Fellow (CRTA) |
Sunmin Lee Ph.D. | Research Chemist |
Shraddha Rastogi Ph.D. | Postdoctoral Fellow (CRTA) |